NCT04515732View on ClinicalTrials.gov

Danish Population-based Assessment of Psoriasis and Psoriatic Arthritis (DANPAPP)

PHASE4UnknownINTERVENTIONAL
Enrollment

115

Participants

Timeline

Start Date

December 14, 2018

Primary Completion Date

April 30, 2021

Study Completion Date

October 31, 2021

Conditions
PsoriasisPsoriatic Arthritis
Interventions
DRUG

Apremilast Oral Tablet

As in description

Trial Locations (2)

2600

Videncenter for Reumatologi og Rygsygdomme, Rigshospitalet Glostrup, Glostrup Municipality

6400

Dansk Gigthospital, Sønderborg

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

collaborator

The Danish Rheumatism Association

OTHER

collaborator

The Danish Psoriasis Association

UNKNOWN

lead

Professor Mikkel Østergaard

OTHER

NCT04515732 - Danish Population-based Assessment of Psoriasis and Psoriatic Arthritis (DANPAPP) | Biotech Hunter | Biotech Hunter